期刊
TRENDS IN CANCER
卷 4, 期 5, 页码 359-373出版社
CELL PRESS
DOI: 10.1016/j.trecan.2018.03.009
关键词
-
类别
资金
- PhD Innovation Fund of Shanghai Jiao Tong University School of Medicine [BXJ201736]
- Shanghai Key Discipline of Medical Imaging [2017ZZ02005]
- University of Wisconsin, Madison
- National Institutes of Health [P30CA014520, T32CA009206, T32GM008505]
- American Cancer Society [125246-RSG-13-099-01-CCE]
- China Scholarship Council (CSC)
- NATIONAL CANCER INSTITUTE [P30CA014520, T32CA009206] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008505] Funding Source: NIH RePORTER
The rapidly evolving field of cancer immunotherapy recently saw the approval of several new therapeutic antibodies. Several cell therapies, for example, chimeric antigen receptor-expressing T cells (CAR-T), are currently in clinical trials for a variety of cancers and other diseases. However, approaches to monitor changes in the immune status of tumors or to predict therapeutic responses are limited. Monitoring lymphocytes from whole blood or biopsies does not provide dynamic and spatial information about T cells in heterogeneous tumors. Positron emission tomography (PET) imaging using probes specific for T cells can noninvasively monitor systemic and intratumoral immune alterations during experimental therapies and may have an important and expanding value in the clinic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据